Regeneron Pharmaceuticals ((REGN)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Regeneron Pharmaceuticals and Sanofi are conducting a Phase 2 clinical study titled ‘A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis.’ The study aims to evaluate how well dupilumab works in treating eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD), focusing on symptom relief and inflammation reduction over a period of 24 to 52 weeks.
The intervention being tested is dupilumab, an experimental drug designed to alleviate symptoms and reduce inflammation associated with EoG and EoD. It is administered to participants aged 12 and older.
This interventional study follows a single-group assignment model without masking, focusing primarily on treatment. Participants receive dupilumab to assess its efficacy and safety.
The study began on April 14, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates are yet to be announced, with the last update submitted on August 20, 2025.
The outcome of this study could significantly impact Regeneron and Sanofi’s market performance, potentially boosting investor confidence if dupilumab proves effective. This development is crucial as the companies compete in the biopharmaceutical industry, particularly in the niche market of eosinophilic gastrointestinal diseases.
The study is ongoing, with further details available on the ClinicalTrials portal.